148 related articles for article (PubMed ID: 3227498)
1. [Responsibility of the pharmaceutical industry toward the first undesirable effects of new products].
Juillet Y; de Cremiers F
Therapie; 1988; 43(5):385-8. PubMed ID: 3227498
[No Abstract] [Full Text] [Related]
2. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
Gleiter CH; Bieck PR
Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
[No Abstract] [Full Text] [Related]
3. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
Offerhaus L
Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
[No Abstract] [Full Text] [Related]
4. ["There are clear criteria for product surveillance studies"].
Throm S
MMW Fortschr Med; 2009 Aug; 151(34-35):7. PubMed ID: 19771777
[No Abstract] [Full Text] [Related]
5. [Information centers on undesirable effects of drugs: also on alerting function].
Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H
Therapie; 1987; 42(2):231-7. PubMed ID: 3617000
[No Abstract] [Full Text] [Related]
6. An underrecognized challenge in evaluating postmarketing drug safety.
Roden DM
Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
[No Abstract] [Full Text] [Related]
7. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
Haramburu F; Pere JC; Begaud B; Albin H
Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
[No Abstract] [Full Text] [Related]
8. Pharmaceutical postmarket review: fact or fiction?
Schanz SJ
Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
[No Abstract] [Full Text] [Related]
9. [Comparative organization of drug monitoring in France and 7 European countries].
Vaissere J; de Cremiers F; Auriche M; Juillet Y
Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
[No Abstract] [Full Text] [Related]
10. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
11. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
[No Abstract] [Full Text] [Related]
12. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
13. [The new norms decreed by the legislative dirrective 91-93 CCE].
Neri M; Palazzo S
Boll Chim Farm; 1998 Feb; 137(2):31-4. PubMed ID: 9595832
[TBL] [Abstract][Full Text] [Related]
14. Possible strategies for early recognition of potential drug safety problems.
Venulet J
Adverse Drug React Acute Poisoning Rev; 1988; 7(1):39-47. PubMed ID: 3389236
[No Abstract] [Full Text] [Related]
15. Post-marketing surveillance of drugs.
Bell KD
Med J Aust; 1991 Apr; 154(8):567. PubMed ID: 2064665
[No Abstract] [Full Text] [Related]
16. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France].
Fermont I;
Therapie; 2002; 57(3):283-8. PubMed ID: 12422543
[TBL] [Abstract][Full Text] [Related]
17. [Drug monitoring].
Royer RJ
Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
[No Abstract] [Full Text] [Related]
18. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
Selbmann HK
MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
[No Abstract] [Full Text] [Related]
19. [Responsibility of the pharmaceutical industry in health safety].
Santini C
Ann Pharm Fr; 1999 Jan; 57(1):10-5; discussion 27-8. PubMed ID: 10073046
[TBL] [Abstract][Full Text] [Related]
20. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
